Brain tumor

Browse Indian Patents from 2005 by Weekly Journals

Bookmark this page:

Join India Patent Agent Exam 2008 Training Course

Join Free Patent Lessons Course

Methods for inhibiting brain tumor growth with the Patent no: 6,521,593 is given in the abstract: The present invention describes methods for inhibition of tumor growth in the brain, using antagonists of integrins such as .alpha..sub.v.beta..sub.3 and .alpha..sub.v.beta..Sub.5. Antagonists of the present invention can inhibit angiogenesis in brain tumor tissue. They can also inhibit vitronectin and tenascin-mediated cell adhesion and migration in brain tumor cells. They can further induce direct brain tumor cell death.

In Patent no: 4,195,017 titled ‘Malignin, derived from brain tumor cells, complexes and polypeptides thereof’ with the abstract: A product, Malignin, derived from brain tumor cells, which cells may be cultured in a suitable nutrient medium for many generations, and the method of preparing same. Malignin may be complexed with an inert carrier, such as bromoacetylcellulose, and employed in tests for brain tumors. The antibody to Malignin is also prepared. A complex of Malignin and an inert carrier may be further complexed with Anti-Malignin.

Some of the other such methods patented are given below.

Patent no: 7,060,275 titled ‘Use of protein biomolecular targets in the treatment and visualization of brain tumors’ with the abstract : The present invention relates to the use of proteins which are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of immunotherapeutic and immunoimaging agents which specifically bind to one or more of human proteins angiopoietin related protein 2 (ARP-2,) secreted protein acidic, rich in cysteine (SPARC,) c-met proto-oncogene (C-MET,) brevican (BEHAB,) CD-44 antigen (CD-44,) tetraspanin 3 (TSPN3,) pleiotrophin (PTN,) osteopontin (OPN,) vasoactive intestinal peptide receptor-2 (VIPR-2,) and receptor protein tyrosine phosphatase zeta (PTP.zeta.) for the treatment and visualization of brain tumors in patients. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention. The present invention also provides novel splice variants of protein PTP.zeta., PTP.zeta. SM1 and PTP.zeta. SM2. Nucleic acid probes specific for the spliced mRNA encoding these variants and affinity reagents specific for the novel proteins are also provided.

Patent no: 6,770,457 titled ‘Process of purifying angiogenesis inhibitors’ with the abstract :The present invention relates to process of purifying the angiogensis inhibitor proteins expressed in E. coli and to the use of recombinant kringle 1-3 (; greenstatin) purified by the above process as a angiogenesis inhibitor and an anticancer agent. Particularly, according to the process of purifying the protein, the angiogenesis inhibitor proteins overexpressed are solubilized, refolded, and purified as a pure and active form. The greenstatin purified by the process specifically suppresses endothelial cell proliferation, anaiogenesis, and the growth of lung cancer, skin cancer, and brain tumor. Therefore, the process of this invention is applicable to the mass-production of angiogenesis inhibitor proteins such as greenstatin which is useful for the treatment of glaucoma, retinopathy, and cancers.

Patent no: 6,699,468 titled ‘Replication-competent herpes simplex virus mediates destruction of neo-plastic cells’ with the abstract : A method for killing malignant brain tumor cells in vivo entails providing replication competent herpes simplex virus vectors to tumor cells. A replication competent herpes simplex virus vector, with defective expression of the .gamma.34.5 gene and the ribonucleotide reductase gene, specifically destroys tumor cells, is hypersensitive to anti-viral agents, and yet is not neurovirulent.